Cor Vasa 2024, 66(4):394-402 | DOI: 10.33678/cor.2024.036

(Prescription of basic pharmacotherapy and its dosage in outpatient care after discharge in patients hospitalized for cardiac decompensation)

Jan Orcta, Otto Mayer Jr.a, b, Simona Bílkováa, b, Tomáš Krynskýa, Josef Jirákc
a II. interní klinika, Lékařská fakulta v Plzni, Univerzita Karlova a Fakultní nemocnice Plzeň, Plzeň, Česká republika
b Biomedicínské centrum, Univerzita Karlova/Lékařská fakulta a Fakultní nemocnice Plzeň, Plzeň, Česká republika
c Správa informačního systému, Fakultní nemocnice Plzeň, Plzeň, Česká republika

Aims: We analyzed the prescription and dosage of essential pharmacotherapy in outpatient care at the end of 2022 in patients hospitalized between 2010-2020 for cardiac decompensation.

Methods: The initial sample included 4097 patients hospitalized for cardiac decompensation. From this cohort, we analyzed 975 surviving patients (mean age 71.9 [±SD 10.8], 62.8% male) regarding pharmacotherapy in their central medication record.

Results: The prescription of beta-blockers (BB) was 79.6% in outpatient care and did not significantly change after discharge from hospitalization (77.5%). Taking BB with evidence in chronic heart failure (HF) only, there was a significant increase in their prescription (from 61.1% to 73.6%). A decrease in prescriptions (from 79% to 74.8%) occurred in outpatient care in renin-angiotensin-aldosterone system (RAAS) blockers, while an increase in SGLT-2 inhibitors (from 0.7% to 20.1%). There was a significant increase in statins in patients with ischemic etiology of HF (from 57.2% to 63%), and markedly in the prescription of sacubitril/valsartan in patients with an ejection fraction ≤40% (from 1.8% to 23.1%). Mineralocorticoid receptor antagonists (MRA) changed minimally (45.3% vs. 43.9%). Regarding the recommended dosage, a marginal increase occurred in RAAS blockers, while we observed a decrease in the dosage of MRA and statins.

Keywords: Guideline-directed medical therapy, Chronic heart failure, Outpatient care,

Received: April 9, 2024; Revised: April 9, 2024; Accepted: May 1, 2024; Prepublished online: June 2, 2012; Published: September 9, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Orct J, Mayer O, Bílková S, Krynský T, Jirák J. (Prescription of basic pharmacotherapy and its dosage in outpatient care after discharge in patients hospitalized for cardiac decompensation). Cor Vasa. 2024;66(4):394-402. doi: 10.33678/cor.2024.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021;23:352-380. Go to original source... Go to PubMed...
    2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726. Go to original source... Go to PubMed...
    3. Krynský T, Mayer O Jr., Bruthans J, et al. Dosing of basic pharmacotherapy and its effect on the prognosis of patients hospitalized for heart failure. Vnitř Lék 2023;69:109-118. Go to original source... Go to PubMed...
    4. Mayer O, Bruthans J, Bilkova S, et al. The prognosis and therapeutic management of patients hospitalized for heart failure in 2010-2020. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2022;166:312-321. Go to original source... Go to PubMed...
    5. Vorlickova P, Mayer O, Bruthans J, et al. The changes in achievement of target LDL-cholesterol levels between 2006 and 2017 in Czech patients with chronic coronary heart disease. Cor Vasa 2019;61:20-27. Go to original source...
    6. Jhund PS, Kondo T, Butt JH, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 2022;28:1956-1964. Go to original source... Go to PubMed...
    7. James S, Erlinge D, Storey RF, et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid 2024;3:EVIDoa2300286. Go to original source... Go to PubMed...
    8. Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2023;81:1835-1878. Go to original source... Go to PubMed...
    9. Khan MS, Fonarow GC, Ahmed A, et al. Dose of Angiotensin--Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. Circ Heart Fail 2017;10:e003956. Go to original source... Go to PubMed...
    10. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. Go to original source... Go to PubMed...
    11. Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173-1184. Go to original source... Go to PubMed...
    12. Bavishi C, Chatterjee S, Ather S, et al. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev 2015;20:193-201. Go to original source... Go to PubMed...
    13. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 2013;346:f55. Go to original source... Go to PubMed...
    14. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13. Go to original source... Go to PubMed...
    15. Simon T, Mary-Krause M, Funck-Brentano C, et al. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J 2003;24:552-559. Go to original source... Go to PubMed...
    16. Zheng SL, Chan FT, Nabeebaccus AA, et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart 2018;104:407-415. Go to original source... Go to PubMed...
    17. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015;131:34-42. Go to original source... Go to PubMed...
    18. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717. Go to original source... Go to PubMed...
    19. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321. Go to original source... Go to PubMed...
    20. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-551. Go to original source... Go to PubMed...
    21. Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019;394:1540-1550. Go to original source... Go to PubMed...
    22. Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022;43:474-484. Go to original source...
    23. Rogers JK, Jhund PS, Perez AC, et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail 2014;2:289-297. Go to original source... Go to PubMed...
    24. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo- -controlled trial. Lancet 2008;372:1231-1239. Go to original source... Go to PubMed...
    25. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 2007;93:914-921. Go to original source... Go to PubMed...
    26. Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397-1405. Go to original source... Go to PubMed...
    27. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-779. Go to original source... Go to PubMed...
    28. Chen X, Kang Y, Dahlström U, Fu M. Impact of adherence to guideline-directed therapy on risk of death in HF patients across an ejection fraction spectrum. ESC Heart Fail 2023;10:3656-3666. Go to original source... Go to PubMed...
    29. Stella BM, Alessandro Z. ICD Implantation Practice Within Europe: How To Explain The Differences Beyond Economy? J Atr Fibrillation 2015;8:1262.

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes